INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15
The R-enantiomer of lansoprazole, dexlansoprazole, is delivered by a unique technology called the dual delayed release formulation. When compared to lansoprazole, the medicine has been demonstrated to be more effective at mending erosive esophagitis. Dexlansoprazole significantly improved the maintenance rates of repaired esophageal mucosa in patients with erosive esophagitis and symptom control in patients with non-erosive reflux syndrome when compared to placebo. Dexlansoprazole is a medication that can be given without concern for food. Overall, dexlansoprazole is well tolerated and has a side-effect profile that is similar to that of lansoprazole.
Keywords:
Mechanism of Action Dexlansoprazole, Pharmacokinetics & Pharmacodynamics, pharmacological properties of dexlansoprazole, Indications for proton pump inhibitors therapy, treatment of gastroesophageal reflux disease.
Cite Article:
"A Review: On Dexlansoprazole", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.7, Issue 4, page no.135 - 142, April-2022, Available :http://www.ijsdr.org/papers/IJSDR2204024.pdf
Downloads:
000337209
Publication Details:
Published Paper ID: IJSDR2204024
Registration ID:200181
Published In: Volume 7 Issue 4, April-2022
DOI (Digital Object Identifier):
Page No: 135 - 142
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631
Facebook Twitter Instagram LinkedIn